These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22035806)

  • 1. Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.
    Einstein MH; Frimer M; Kuo DY; Reimers LL; Mehta K; Mutyala S; Huang GS; Hou JY; Goldberg GL
    Gynecol Oncol; 2012 Jan; 124(1):21-5. PubMed ID: 22035806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial.
    Frimer M; Miller EM; Shankar V; Girda E; Mehta K; Smith HO; Kuo DYS; Goldberg GL; Einstein MH
    Int J Gynecol Cancer; 2018 Nov; 28(9):1781-1788. PubMed ID: 30371562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.
    Low JS; Wong EH; Tan HS; Yap SP; Chua EJ; Sethi VK; Soh LT; Low J; Tay EH; Chew SH
    Gynecol Oncol; 2005 Apr; 97(1):171-7. PubMed ID: 15790454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
    Fader AN; Nagel C; Axtell AE; Zanotti KM; Kelley JL; Moore KN; Secord AA; Walsh CS; Huh WK; Gehrig PA; Gibbons H; Rose PG; Havrilesky LJ; Tuller E; Drake RD; Bottsford-Miller J; O'Malley DM;
    Gynecol Oncol; 2009 Mar; 112(3):558-62. PubMed ID: 19118888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
    Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
    Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
    Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of chemotherapy and radiation in uterine papillary serous carcinoma.
    Viswanathan AN; Macklin EA; Berkowitz R; Matulonis U
    Gynecol Oncol; 2011 Dec; 123(3):542-7. PubMed ID: 21963091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
    Obermair A; Mileshkin L; Bolz K; Kondalsamy-Chennakesavan S; Cheuk R; Vasey P; Wyld D; Goh J; Nicklin JL; Perrin LC; Sykes P; Janda M
    Gynecol Oncol; 2011 Feb; 120(2):179-84. PubMed ID: 21126755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].
    Xue DB; Ding LJ; Xia AL; Chen D; Xia HP; Teng XD; Xu ST; Zhang SJ; Ren XC
    Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):671-4. PubMed ID: 21176532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
    Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
    Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
    Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
    Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
    Einstein MH; Klobocista M; Hou JY; Lee S; Mutyala S; Mehta K; Reimers LL; Kuo DY; Huang GS; Goldberg GL
    Gynecol Oncol; 2012 Jan; 124(1):26-30. PubMed ID: 22055846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
    Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
    Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
    Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
    Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study.
    Fakiris AJ; Moore DH; Reddy SR; Look KY; Yiannoutsos CT; Randall ME; Cardenes HR;
    Gynecol Oncol; 2005 Mar; 96(3):818-23. PubMed ID: 15721431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.